BLOOMFIELD, Conn., Jan. 31, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will be hosting its Investor Day on Thursday, March 7, 2024 in New York City.
The event will begin at 8:30 a.m. ET featuring in-depth presentations on corporate strategy and financial targets. A live webcast of the presentation will be available here in the Investor Relations section of The Cigna Group's website.
To listen to this presentation live on the Internet, visit https://investors.thecignagroup.com/events-and-presentations/default.aspx at least 15 minutes prior to the presentation to download and install any necessary audio software.
About The Cigna Group
The Cigna Group (NYSE: CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Evernorth Health Services, Cigna Healthcare, or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 countries and jurisdictions, and has approximately 165 million customer relationships around the world. Learn more at thecignagroup.com.
Investor Relations Contact
Ralph Giacobbe
1 (860) 787-7968
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Justine Sessions
1 (860) 810-6523
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$300.73 |
| Daily Change: | -5.40 -1.76 |
| Daily Volume: | 1,067,621 |
| Market Cap: | US$80.270B |
June 12, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
